Novartis has confirmed a deal worth a potential $170 million with Spark Therapeutics to develop and commercialise its gene therapy Luxturna (voretigene neparvovec) in markets outside the US, where it is already approved by the FDA for confirmed biallelic RPE65 mutation-associated retinal dystrophy – an inherited eye condition which can lead to complete blindness in some patients.
Spark hands over Luxturna rights outside US to Novartis for $170m
